Acknowledgments The authors thank the external reviewers, Allan Grill MD, CCFP (COE), MPH, FCFP, CCPE and Kelly Picard PhD, RD, CDE, for their insightful feedback and for the lending of their time and expertise
Many patients bring notes about Their target weight or overall health goals Eating habits that feel challenging Times of day when hunger is strongest Energy crashes or mood fluctuations Any symptoms they want addressed This information helps your provider customize your treatment plan and address both metabolic and lifestyle concerns
doi: 10.1007/s00125-002-0878-6
But in 2025, thats changing: Compounded tirzepatide was effectively banned by the FDA after March 19, 2024 Compounded semaglutide ends May 22, 2024 (unless extended) Outside of narrow exceptions, compounded GLP-1 weight loss medications are no longer permitted by the FDA